ALPS Advisors’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $516K | Buy |
+141,664
| New | +$516K | ﹤0.01% | 627 |
|
|
2019
Q2 | – | Sell |
-282,329
| Closed | -$2.31M | – | 879 |
|
|
2019
Q1 | $2.31M | Buy |
282,329
+61,934
| +28% | +$507K | 0.02% | 209 |
|
|
2018
Q4 | $1.22M | Buy |
220,395
+119,447
| +118% | +$661K | 0.01% | 266 |
|
|
2018
Q3 | $891K | Buy |
100,948
+18,399
| +22% | +$162K | 0.01% | 434 |
|
|
2018
Q2 | $824K | Buy |
82,549
+19,151
| +30% | +$191K | 0.01% | 380 |
|
|
2018
Q1 | $604K | Buy |
63,398
+11,019
| +21% | +$105K | ﹤0.01% | 420 |
|
|
2017
Q4 | $779K | Buy |
52,379
+6,007
| +13% | +$89.3K | 0.01% | 308 |
|
|
2017
Q3 | $912K | Buy |
46,372
+11,323
| +32% | +$223K | 0.01% | 258 |
|
|
2017
Q2 | $504K | Buy |
35,049
+2,079
| +6% | +$29.9K | ﹤0.01% | 485 |
|
|
2017
Q1 | $303K | Sell |
32,970
-3,860
| -10% | -$35.5K | ﹤0.01% | 689 |
|
|
2016
Q4 | $383K | Sell |
36,830
-11,630
| -24% | -$121K | ﹤0.01% | 619 |
|
|
2016
Q3 | $439K | Sell |
48,460
-4,890
| -9% | -$44.3K | ﹤0.01% | 368 |
|
|
2016
Q2 | $399K | Buy |
53,350
+10,728
| +25% | +$80.2K | ﹤0.01% | 459 |
|
|
2016
Q1 | $384K | Buy |
42,622
+2,270
| +6% | +$20.5K | ﹤0.01% | 569 |
|
|
2015
Q4 | $521K | Sell |
40,352
-4,785
| -11% | -$61.8K | 0.01% | 388 |
|
|
2015
Q3 | $4.36K | Buy |
45,137
+16,533
| +58% | +$1.6K | ﹤0.01% | 603 |
|
|
2015
Q2 | $294K | Buy |
28,604
+18,563
| +185% | +$191K | ﹤0.01% | 658 |
|
|
2015
Q1 | $112K | Buy |
+10,041
| New | +$112K | ﹤0.01% | 654 |
|